{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:09:43Z","timestamp":1779106183402,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:p>The integrase strand transfer inhibitor (INSTI)-resistance mutations Q148H\/K\/R are arguably the most important INSTI-resistance mutations as they represented the first step to high-level dolutegravir cross-resistance. We describe an individual with transmitted four-class drug resistance whose virus sequence had the previously uncharacterized mutation Q148N. Infectious molecular HIV-1 clones containing Q148N alone and in combination with G140S demonstrated \u223c2.4\u20134.5 reduced elvitegravir susceptibility depending on the virus's genetic context but retained susceptibility to raltegravir and dolutegravir. This level of reduced elvitegravir susceptibility is lower than that observed with Q148H\/K\/R and in fact the infected individual responded to an initial treatment regimen containing tenofovir\/emtricitabine\/elvitegravir\/cobicistat. Q148N was associated with a higher replication capacity than Q148H, suggesting that this mutation may be more fit in the absence of selective INSTI therapy.<\/jats:p>","DOI":"10.1089\/aid.2016.0038","type":"journal-article","created":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T22:03:32Z","timestamp":1458770612000},"page":"702-704","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility"],"prefix":"10.1177","volume":"32","author":[{"given":"Vici","family":"Varghese","sequence":"first","affiliation":[{"name":"Stanford University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin A.","family":"Pinsky","sequence":"additional","affiliation":[{"name":"Stanford University"},{"name":"Stanford University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darvin S.","family":"Smith","sequence":"additional","affiliation":[{"name":"Stanford University"},{"name":"Kaiser Permanente Medical Care Program\u2013Northern California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Klein","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Medical Care Program\u2013Northern California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Shafer","sequence":"additional","affiliation":[{"name":"Stanford University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,7,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.920-928.2000"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.66.11.6361-6369.1992"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M511348200"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04844-14"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis750"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg100"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit697"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv202"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv243"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2780"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1749"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/2325957415596229"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1748"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01345-09"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2016.0038","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2016.0038","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2016.0038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:14:58Z","timestamp":1779102898000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/aid.2016.0038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1089\/aid.2016.0038"],"URL":"https:\/\/doi.org\/10.1089\/aid.2016.0038","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}